SouthState’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$17.4K Buy
23
+2
+10% +$1.51K ﹤0.01% 639
2026
Q2
$13.1K Sell
21
-2
-9% -$1.36K ﹤0.01% 661
2026
Q1
$17.8K Sell
23
-9
-28% -$6.89K ﹤0.01% 577
2025
Q4
$24.7K Buy
32
+7
+28% +$4.75K ﹤0.01% 551
2025
Q3
$14.1K Sell
25
-20
-44% -$11.3K ﹤0.01% 623
2025
Q2
$23.6K Sell
45
-7
-13% -$3.91K ﹤0.01% 620
2025
Q1
$33K Buy
52
+44
+550% +$30.3K ﹤0.01% 600
2024
Q4
$5.7K Buy
8
+3
+60% +$2.52K ﹤0.01% 557
2024
Q3
$5.26K Hold
5
– – ﹤0.01% 519
2024
Q2
$5.26K Buy
5
+4
+400% +$3.88K ﹤0.01% 532
2024
Q1
$962 Buy
+1
New +$951 ﹤0.01% 649
2023
Q2
– Sell
-8
Closed -$6.57K – 637
2023
Q1
$6.57K Sell
8
-25
-76% -$18.9K ﹤0.01% 551
2022
Q4
$23.8K Hold
33
– – ﹤0.01% 450
2022
Q3
$23K Buy
33
+8
+32% +$5.04K ﹤0.01% 451
2022
Q2
$15K Hold
25
– – ﹤0.01% 533
2022
Q1
$17K Hold
25
– – ﹤0.01% 549
2021
Q4
$16K Hold
25
– – ﹤0.01% 513
2021
Q3
$15K Buy
+25
New +$15.5K ﹤0.01% 458

Other funds holding REGN

SouthState's REGN Position: Q3 2026 in Review

SouthState increased its Regeneron Pharmaceuticals (REGN) stake by 9.5% in Q3 2026, buying an estimated $1.51K and bringing the position to 23 shares worth $17.4K. The position accounts for ﹤0.01% of the portfolio, ranked #639.

SouthState first reported a position in REGN in Q3 2021 and has held it in 18 quarters since. The position peaked at $33K in Q1 2025. 1,229 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • SouthState held 23 shares of Regeneron Pharmaceuticals worth $17.4K as of Q3 2026.
  • SouthState bought 2 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $1.51K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of SouthState's portfolio in Q3 2026, its #639 holding.
  • SouthState first reported a position in Regeneron Pharmaceuticals in Q3 2021 and has held it in 18 quarters since.
  • SouthState's Regeneron Pharmaceuticals position peaked at $33K in Q1 2025.
  • 1,229 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on SouthState's 13F filing for Q3 2026, filed 9 Nov 2026.